查找临床试验
已按「肺癌」检索，对应国际通用词 lung cancer
共找到 2,325 项正在招募的试验
数据更新于 22:08，每 5 分钟自动同步Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients
Mexico
年龄 18 Years – 75 Years
Instituto Nacional de Cancerologia de Mexico
The Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.
China
年龄 18 Years – 75 Years
Sun Yat-sen University
RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC
China
年龄 18 Years – 不限
Xueqin Yang
Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)
South Korea
年龄 20 Years – 不限
Pusan National University Hospital
Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC
China
年龄 18 Years – 不限
The First Affiliated Hospital of Xiamen University
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
United States、Puerto Rico
年龄 18 Years – 80 Years
VM Oncology, LLC
Pulmonary Rehabilitation in Advanced Lung Cancer Survivors
United States
年龄 18 Years – 不限
Case Comprehensive Cancer Center
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
China
年龄 18 Years – 不限
Guangzhou Institute of Respiratory Disease
Study on the Microbial Environment of Non-small Cell Lung Cancer Based on Mycogenomics and Its Clinical Relevance
China
年龄 30 Years – 80 Years
958th Army Hospital of the Chinese People's Liberation Army
Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
China
年龄 18 Years – 不限
Tianjin Medical University Cancer Institute and Hospital
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
China
年龄 18 Years – 不限
Beijing Tide Pharmaceutical Co., Ltd
Pathological Response After Neoadjuvant Treatment on NSCLC
Spain
年龄 18 Years – 不限
Fundación GECP